Profile
International Journal of Clinical Pharmacology & Pharmacotherapy Volume 5 (2020), Article ID 5:IJCPP-146, 6 pages
https://doi.org/10.15344/2456-3501/2020/146
Original Article
Awareness of Rapid-onset Opioid Formulations among Healthcare Professionals with Experience in Palliative Care: A Questionnaire Survey

Eiji Kose*,1, Taesong An2, Akihiko Kikkawa2 and NobuhiroYasuno1,3

1Department of Pharmacy, Teikyo University School of Medicine University Hospital, 2-11-1 Kaga, Itabashi-ku, Tokyo 274-8555, Japan
2Department of Pharmacy, Yokosuka Kyousai Hospital, 1-16 Yonegahamadohri, Yokosuka-shi, Kanagawa 238-8588, Japan
3Laboratory of Hospital Pharmacy, School of Pharmacy, Teikyo University, 2-11-1 Kaga, Itabashi-ku, Tokyo 274-8555, Japan
Dr. Eiji Kose, Department of Pharmacy, Teikyo University School of Medicine University Hospital 2-11-1 Kaga, Itabashi-ku, Tokyo 274-8555, Japan, Phone No: +81-3-3964-1211, Fax No: +81-3-3964-9426; E-mail: kose.eiji@med.teikyo-u.ac.jp
01 April 2020; 26 May 2020; 28 May 2020
Kose E, An T, Kikkawa A, Yasuno N (2020) Awareness of Rapid-onset Opioid Formulations among Healthcare Professionals with Experience in Palliative Care: A Questionnaire Survey. Int J Clin Pharmacol Pharmacother 5: 146. doi: https://doi.org/10.15344/2456-3501/2020/146

Abstract

Background: The present study was conducted to determine the level of awareness about the difference between Short-Acting Opioid (SAO) and Rapid-Onset Opioid (ROO) formulation.
Methods: A questionnaire survey was conducted to evaluate levels of awareness regarding the definition of cancer breakthrough pain, how to use the ROO formulation, and the difference between SAO and ROO formulation among physicians, nurses, and pharmacists with experience in palliative care. The surveillance period is between December 1, 2017 and December 31, 2017.
Results: The recovery rate of the questionnaire was 72.7%. We received responses from 25 physicians, 76 nurses, and 77 hospital pharmacists. The awareness of the difference between SAO formulation and ROO formulation across all occupation groups was approximately 4.8 in 11 steps from 0 to 10. The differences between SAO and ROO formulation were associated with " the starting dose does not depend on the daily dose of the opioid analgesic being administered on time", "restriction of the number of doses in ROO formulation", "duration of effect", "drug intake method (AbstralĀ® Sublingual Tablets)", " approximate cost", and "occupations". It was indicated that the recognition on the proper use of ROO formulation was low even in the healthcare professionals with experience in palliative care.
Conclusion: The results of the present study suggest that it is necessary for each healthcare professional to reconfirm their knowledge of ROO formulation in the future and ensure appropriate administration.